{"filepath": "../L2M3_data/0_csd_related_papers/ACS_XML/ja016384q.xml", "publisher": "acs", "elements": [{"idx": 1, "type": "text", "classification": ["else"], "content": "<title></title><p>Calcium-containing crystal deposition diseases represent a\ngroup of clinically heterogeneous calcific diseases that are a\nsignificant source of morbidity. Phosphorylated carboxylic acids\nare powerful inhibitors of biological crystallization as it relates\nto those diseases. Phosphocitrate (PC), a naturally occurring\ncompound (Chart ), is particularly potent. It has been demonstrated to inhibit the transformation of calcium phosphate to\nhydroxyapatite (Ca<sub>5</sub>(PO<sub>4</sub>)<sub>3</sub>(OH)), the deposition of calcium\noxalates, the crystallization of octacalcium phosphate (Ca<sub>8</sub>(HPO<sub>4</sub>)<sub>2</sub>(PO<sub>4</sub>)<sub>4</sub>\u00b75H<sub>2</sub>O), and calcium pyrophosphate (Ca<sub>2</sub>P<sub>2</sub>O<sub>7</sub>\u00b72H<sub>2</sub>O), and the formation of struvite (Mg(NH<sub>4</sub>)(PO<sub>4</sub>)\u00b76H<sub>2</sub>O) in\nvivo. PC has also expressed inhibitory activity against the\nformation of scaling Ca salts, such as calcite (CaCO<sub>3</sub>) and gypsum\n(CaSO<sub>4</sub>\u00b72H<sub>2</sub>O), related to industrial water treatment. In addition,\nallied to these later actions, PC has been noted to prevent corrosion\nof carbon steel surfaces. Overall then, the compound attracts keen\ninterest from the viewpoint of its nontoxic nature and potential\nto influence biomineralization in many diverse biological fields.\n\n</p>", "clean_text": "\n\nCalcium-containing crystal deposition diseases represent a group of clinically heterogeneous calcific diseases that are a significant source of morbidity. Phosphorylated carboxylic acids are powerful inhibitors of biological crystallization as it relates to those diseases. Phosphocitrate (PC), a naturally occurring compound (Chart ), is particularly potent. It has been demonstrated to inhibit the transformation of calcium phosphate to hydroxyapatite (Ca5(PO4)3(OH)), the deposition of calcium oxalates, the crystallization of octacalcium phosphate (Ca8(HPO4)2(PO4)4\u22c55H2O), and calcium pyrophosphate (Ca2P2O7\u22c52H2O), and the formation of struvite (Mg(NH4)(PO4)\u22c56H2O) in vivo. PC has also expressed inhibitory activity against the formation of scaling Ca salts, such as calcite (CaCO3) and gypsum (CaSO4\u22c52H2O), related to industrial water treatment. In addition, allied to these later actions, PC has been noted to prevent corrosion of carbon steel surfaces. Overall then, the compound attracts keen interest from the viewpoint of its nontoxic nature and potential to influence biomineralization in many diverse biological fields.  ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 2, "type": "figure", "classification": null, "content": "<fig fig-type=\"chart\" id=\"ja016384qc00001\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Schematic Structure of Phosphocitric Acid (H<sub>5</sub>PC)\n</p>\n</caption>\n<graphic orientation=\"portrait\" position=\"float\" xlink:href=\"ja016384qc00001.tif\"></graphic>\n</fig>", "clean_text": " 1  Schematic Structure of Phosphocitric Acid (H5PC)    ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 3, "type": "text", "classification": ["else"], "content": "<p>In this paper we describe the preparation and crystal and\nmolecular structure of a polymeric mixed salt of PC, namely\n[CaNa(PC)<sub>2</sub>(H<sub>2</sub>O)]<italic toggle=\"yes\">\n<sub>n</sub>\n</italic> (CaNaPC), and its improved calcification\ninhibition properties compared to its precursor, NaPC.\n</p>", "clean_text": "In this paper we describe the preparation and crystal and molecular structure of a polymeric mixed salt of PC, namely [CaNa(PC)2(H2O)] n  (CaNaPC), and its improved calcification inhibition properties compared to its precursor, NaPC. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 4, "type": "text", "classification": ["else"], "content": "<p>CaNaPC forms by the reaction of NaPC and Ca<sup>2+</sup> at pH \u223c2\naccording to the balanced equation (protons on PC also shown):\n<disp-formula content-type=\"pre-labeled\" id=\"ja016384qe00001\">\n<graphic orientation=\"portrait\" position=\"anchor\" xlink:href=\"ja016384qe00001.gif\"></graphic>\n</disp-formula>\nThe structure of CaNaPC (Figure ) can be described as\npolymeric in nature with Ca(PC)<sub>2</sub>(H<sub>2</sub>O) \u201cmonomers\u201d linked\nthrough Na<sup>+</sup> bridges.\n\n</p>", "clean_text": "CaNaPC forms by the reaction of NaPC and Ca2+ at pH ~2 according to the balanced equation (protons on PC also shown):    The structure of CaNaPC (Figure ) can be described as polymeric in nature with Ca(PC)2(H2O) \"monomers\" linked through Na+ bridges.  ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 5, "type": "figure", "classification": null, "content": "<fig id=\"ja016384qf00001\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>ORTEP diagram (50% probability ellipsoids) of CaNaPC. Important bond lengths and distances (\u00c5):\u2009 Ca\u00b7\u00b7\u00b7Ca 8.794(1), Ca\u00b7\u00b7\u00b7Na 4.3972(5), Ca(1)\u2212O(11) 2.388(2), Ca(1)\u2212O(3) 2.446(2), Ca(1)\u2212O(7) 2.477(1), Ca(1)\u2212O(8) 2.527(2), Ca(1)\u2212O(5) 2.586(2). O-attached protons and two hydrogen bonds (dashed lines) are shown. See Supporting Information for further structural details.</p>\n</caption>\n<graphic orientation=\"portrait\" position=\"float\" xlink:href=\"ja016384qf00001.tif\"></graphic>\n</fig>", "clean_text": " 1  ORTEP diagram (50% probability ellipsoids) of CaNaPC. Important bond lengths and distances (\u00c5): Ca\u22c5\u22c5\u22c5Ca 8.794(1), Ca\u22c5\u22c5\u22c5Na 4.3972(5), Ca(1)-O(11) 2.388(2), Ca(1)-O(3) 2.446(2), Ca(1)-O(7) 2.477(1), Ca(1)-O(8) 2.527(2), Ca(1)-O(5) 2.586(2). O-attached protons and two hydrogen bonds (dashed lines) are shown. See Supporting Information for further structural details.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 6, "type": "text", "classification": "error", "content": "<p>Ca is coordinated by four phosphate, four carbonyl, and one\nwater O-atoms defining an irregular polyhedron. Coordination\nnumber nine for Ca is rather rare. In that regard, the unexpected\npresence of a coordinated H<sub>2</sub>O is the result of the strain imposed\nby the PC ligand on the coordination geometry, making a wide\nsite available to H<sub>2</sub>O. Two biologically relevant examples of nine-coordinate Ca are \u03b2-calcium-pyrophosphate and hydroxyapatite. An intriguing feature in the structure of CaNaPC is the\nshort distance of 2.477(1) \u00c5 between Ca and the ester <italic toggle=\"yes\">O</italic> from\nC\u2212<italic toggle=\"yes\">O</italic>-PO<sub>3</sub>H<sub>2</sub>. For comparison, the Ca\u2212O(pyrophosphate ester)\ndistance in \u03b2-Ca<sub>2</sub>(P<sub>2</sub>O<sub>7</sub>) is 2.855 \u00c5. Interestingly, this is consistent\nwith the apparent resistance of the P\u2212O\u2212C moiety to hydrolysis\nin an acidic environment, suggesting that strong calcium coordination exerts a prominent protective effect on the overall\nmolecule. The carbonyl oxygens are coordinated to the Ca center\nwith Ca\u2212O distances in the 2.446(2)\u22122.586(2) \u00c5 range, much\nshorter than those in Ca hydrogen citrate trihydrate (2.37\u22122.49\n\u00c5). Similarly, the Ca\u2212O(PO<sub>2</sub>H) distance is 2.527(2) \u00c5, much\nlonger than Ca\u2212O distances in related complexes (2.3\u22122.4 \u00c5).\nCa\u2212O distances become elongated as coordination number\nincreases. Ca\u2212O distances in CaNaPC are consistent with these\nobservations. All \u2212COOH groups are protonated due to the low\npH of preparation. There are three dissociated protons <italic toggle=\"yes\">per two\nPC </italic>\n<italic toggle=\"yes\">molecules</italic>, all coming from \u2212PO<sub>3</sub>H<sub>2</sub>. Unexpectedly, the\nsecond proton from \u2212PO<sub>3</sub>H is dissociated before that from\n\u03b1-COOH and is involved in a short hydrogen bond (2.453(3) \u00c5)\n\nconnecting adjacent \u201cribbons\u201d. An oxygen from PO<sub>4</sub> bridges Ca<sup>2+</sup>\nand Na<sup>+</sup>. The latter, are six-coordinate, a feature commonly found\nin Na-carboxylate salts. Other structural features of CaNaPC\ncompare well with those of NaPC.\n</p>", "clean_text": "Ca is coordinated by four phosphate, four carbonyl, and one water O-atoms defining an irregular polyhedron. Coordination number nine for Ca is rather rare. In that regard, the unexpected presence of a coordinated H2O is the result of the strain imposed by the PC ligand on the coordination geometry, making a wide site available to H2O. Two biologically relevant examples of nine-coordinate Ca are \u03b2-calcium-pyrophosphate and hydroxyapatite. An intriguing feature in the structure of CaNaPC is the short distance of 2.477(1) \u00c5 between Ca and the ester O from C-O-PO3H2. For comparison, the Ca-O(pyrophosphate ester) distance in \u03b2-Ca2(P2O7) is 2.855 \u00c5. Interestingly, this is consistent with the apparent resistance of the P-O-C moiety to hydrolysis in an acidic environment, suggesting that strong calcium coordination exerts a prominent protective effect on the overall molecule. The carbonyl oxygens are coordinated to the Ca center with Ca-O distances in the 2.446(2)-2.586(2) \u00c5 range, much shorter than those in Ca hydrogen citrate trihydrate (2.37-2.49 \u00c5). Similarly, the Ca-O(PO2H) distance is 2.527(2) \u00c5, much longer than Ca-O distances in related complexes (2.3-2.4 \u00c5). Ca-O distances become elongated as coordination number increases. Ca-O distances in CaNaPC are consistent with these observations. All -COOH groups are protonated due to the low pH of preparation. There are three dissociated protons per two PC  molecules, all coming from -PO3H2. Unexpectedly, the second proton from -PO3H is dissociated before that from \u03b1-COOH and is involved in a short hydrogen bond (2.453(3) \u00c5)  connecting adjacent \"ribbons\". An oxygen from PO4 bridges Ca2+ and Na+. The latter, are six-coordinate, a feature commonly found in Na-carboxylate salts. Other structural features of CaNaPC compare well with those of NaPC. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 7, "type": "text", "classification": ["else"], "content": "<p>There is a considerable amount of evidence on the efficiency\nof PC to restrict pathological mineralization in vivo, despite its\nrapid excretion. A slower, more sustained release form of this\ncompound could therefore offer greater therapeutic benefits.\nSolubility of Ca<sup>2+</sup> salts is typically much lower than that of the\nanalogous Na<sup>+</sup> salts. This prompted the present comparison study\nof its effects to inhibit hardening of an induced plaque in rats.\nChemical induction of calcergy has been described previously\nby Doyle et al., and this model has been used to demonstrate\nbiological potency of PC. In the present work, male Hooded\nWistar rats (200 g) were randomly divided into three groups of\nfive for treatment:\u2009 A = controls; B = sodium phosphocitrate\n(NaPC, administered as Na<sub>4</sub>(HPC)\u00b73H<sub>2</sub>O); and C = calcium\nphosphocitrate (CaNaPC, administered as {CaNa(H<sub>3</sub>PC)(H<sub>4</sub>PC)(H<sub>2</sub>O)}<italic toggle=\"yes\">\n<sub>n</sub>\n</italic>). At all times, rats had access to water and chow ad\nlibitum.\n</p>", "clean_text": "There is a considerable amount of evidence on the efficiency of PC to restrict pathological mineralization in vivo, despite its rapid excretion. A slower, more sustained release form of this compound could therefore offer greater therapeutic benefits. Solubility of Ca2+ salts is typically much lower than that of the analogous Na+ salts. This prompted the present comparison study of its effects to inhibit hardening of an induced plaque in rats. Chemical induction of calcergy has been described previously by Doyle et al., and this model has been used to demonstrate biological potency of PC. In the present work, male Hooded Wistar rats (200 g) were randomly divided into three groups of five for treatment: A = controls; B = sodium phosphocitrate (NaPC, administered as Na4(HPC)\u22c53H2O); and C = calcium phosphocitrate (CaNaPC, administered as {CaNa(H3PC)(H4PC)(H2O)} n ). At all times, rats had access to water and chow ad libitum. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 8, "type": "text", "classification": ["else"], "content": "<p>Plaque formation was chemically induced on day 1 by\nsubcutaneous injection of a 0.1% KMnO<sub>4</sub> solution (200 \u03bcL dose)\nin two positions on either side of the interscapular region.\nRespective salts of PC were dissolved in 0.1 M Tris-HCl (pH\n7.2) and 6 h after plaque initiation, treatment was commenced\nwhereby Group A were injected intraperitoneally with 300 \u03bcL\nof buffer alone, Group B received 300 \u03bcL of NaPC solution (9.7\nmg as H<sub>5</sub>PC) in buffer, and Group C 300 \u03bcL of CaNaPC solution\n(9.6 mg as H<sub>5</sub>PC). Thereafter, therapy with the aforementioned\ntreatments was given on alternate days. Calcification of plaques\nwas allowed to proceed over 10 days at which time the experiment\nwas terminated and the plaque material present was excised and\nweighed. It had previously been established that there was a direct\nrelationship between plaque weight and precipitation of hydroxyapatite. Results are presented in Table .\n\n</p>", "clean_text": "Plaque formation was chemically induced on day 1 by subcutaneous injection of a 0.1% KMnO4 solution (200 \u03bcL dose) in two positions on either side of the interscapular region. Respective salts of PC were dissolved in 0.1 M Tris-HCl (pH 7.2) and 6 h after plaque initiation, treatment was commenced whereby Group A were injected intraperitoneally with 300 \u03bcL of buffer alone, Group B received 300 \u03bcL of NaPC solution (9.7 mg as H5PC) in buffer, and Group C 300 \u03bcL of CaNaPC solution (9.6 mg as H5PC). Thereafter, therapy with the aforementioned treatments was given on alternate days. Calcification of plaques was allowed to proceed over 10 days at which time the experiment was terminated and the plaque material present was excised and weighed. It had previously been established that there was a direct relationship between plaque weight and precipitation of hydroxyapatite. Results are presented in Table .  ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 9, "type": "table", "classification": null, "content": "<table-wrap id=\"ja016384qt00001\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Inhibitory Action of NaPC and CaNaPC on Plaque Formation<italic toggle=\"yes\">\n<sup>a</sup>\n</italic>\n<sup></sup>\n</p>\n</caption>\n<oasis:table colsep=\"2\" rowsep=\"2\">\n<oasis:tgroup cols=\"4\">\n<oasis:colspec colname=\"1\" colnum=\"1\"></oasis:colspec>\n<oasis:colspec colname=\"2\" colnum=\"2\"></oasis:colspec>\n<oasis:colspec colname=\"3\" colnum=\"3\"></oasis:colspec>\n<oasis:colspec colname=\"4\" colnum=\"4\"></oasis:colspec>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry nameend=\"1\" namest=\"1\">treatment\ngroups</oasis:entry>\n<oasis:entry nameend=\"2\" namest=\"2\">treatment\u2009dosage\n(as\u2009mg\u2009H<sub>5</sub>PC)</oasis:entry>\n<oasis:entry nameend=\"3\" namest=\"3\">plaque\u2009weight\n(mg)<italic toggle=\"yes\">\n<sup>b</sup>\n</italic>\n<sup></sup>\n</oasis:entry>\n<oasis:entry nameend=\"4\" namest=\"4\">plaque\u2009weight\nreduction\u2009(%)\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry colname=\"1\">Group\u2009A\n</oasis:entry>\n<oasis:entry colname=\"2\">0\n</oasis:entry>\n<oasis:entry colname=\"3\">211\u2009\u00b1\u20099.244\n</oasis:entry>\n<oasis:entry colname=\"4\">0\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry colname=\"1\">Group\u2009B\n</oasis:entry>\n<oasis:entry colname=\"2\">9.7\n</oasis:entry>\n<oasis:entry colname=\"3\">147\u2009\u00b1\u20098.825\n</oasis:entry>\n<oasis:entry colname=\"4\">30\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry colname=\"1\">Group\u2009C\n</oasis:entry>\n<oasis:entry colname=\"2\">9.6\n</oasis:entry>\n<oasis:entry colname=\"3\">11\u2009\u00b1\u20094.444\n</oasis:entry>\n<oasis:entry colname=\"4\">95</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<p>\n<italic toggle=\"yes\">\n<sup>a</sup>\n</italic>\n<sup></sup>\u2009Data were processed to establish one way analysis of variance with\nsignificance determined as a pairwise comparison (Student\u2212Newman\u2212Keuls method).<italic toggle=\"yes\">\n<sup>b</sup>\n</italic>\n<sup></sup>\u2009Results are expressed as mean \u00b1 SEM for 10 plaques.\nStatistical significance was determined at the level of <italic toggle=\"yes\">P</italic> &lt; 0.001 for\nsingle groups and pairwise group comparisons.</p>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 10, "type": "text", "classification": "error", "content": "<p>NaPC is an effective plaque inhibitor but at higher and more\nfrequently administered doses. However, as shown in results\nfrom Group B, its effectiveness diminishes when a lower dose is\nused (9.7 mg as H<sub>5</sub>PC), resulting in only 30% plaque reduction.\nSuperior inhibition activity becomes evident by following the\nCaNaPC treatment (Group C), with an equal dose (9.6 mg as\nH<sub>5</sub>PC) giving nearly quantitative (95%) plaque inhibition.\n</p>", "clean_text": "NaPC is an effective plaque inhibitor but at higher and more frequently administered doses. However, as shown in results from Group B, its effectiveness diminishes when a lower dose is used (9.7 mg as H5PC), resulting in only 30% plaque reduction. Superior inhibition activity becomes evident by following the CaNaPC treatment (Group C), with an equal dose (9.6 mg as H5PC) giving nearly quantitative (95%) plaque inhibition. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 11, "type": "text", "classification": ["else"], "content": "<p>Possible explanations for the improved anti-calcification activity\nof CaNaPC compared to NaPC could lie with (a) the slower\nrelease of \u201cactive\u201d PC, thus ensuring its bioavailability at all times\nby limiting the excreted amount, and (b) the more effective\nstereospecific interaction between CaNaPC and crystal face(s) of\nhydroxyapatite. This latter probability could be resolved through\nfuture molecular modeling, as the interaction of NaPC with other\ncalcium crystallites has been reported.\n</p>", "clean_text": "Possible explanations for the improved anti-calcification activity of CaNaPC compared to NaPC could lie with (a) the slower release of \"active\" PC, thus ensuring its bioavailability at all times by limiting the excreted amount, and (b) the more effective stereospecific interaction between CaNaPC and crystal face(s) of hydroxyapatite. This latter probability could be resolved through future molecular modeling, as the interaction of NaPC with other calcium crystallites has been reported. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 12, "type": "text", "classification": ["else"], "content": "<p>In summary, the results presented here reveal a unique neutral\norganic\u2212inorganic hybrid system that can be synthesized under\nmild conditions. The polymeric structure of CaNaPC combines\ninteresting features that include a nine-coordinate Ca center, a\nCa\u2212O(phosphate ester) linkage, and Ca\u2212O\ue5fbC bonding (from\nprotonated carboxylate). CaNaPC is a potent inhibitor of plaque\nformation in vivo, as demonstrated by calcification inhibition\nexperiments on rats. Future studies in our laboratories will focus\non efforts to delineate the inhibition mechanisms both in vitro\nand in vivo. Such studies are currently underway.\n</p>", "clean_text": "In summary, the results presented here reveal a unique neutral organic-inorganic hybrid system that can be synthesized under mild conditions. The polymeric structure of CaNaPC combines interesting features that include a nine-coordinate Ca center, a Ca-O(phosphate ester) linkage, and Ca-O\ue5fbC bonding (from protonated carboxylate). CaNaPC is a potent inhibitor of plaque formation in vivo, as demonstrated by calcification inhibition experiments on rats. Future studies in our laboratories will focus on efforts to delineate the inhibition mechanisms both in vitro and in vivo. Such studies are currently underway. ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 13, "type": "text", "classification": ["else"], "content": "<title>\n<ext-link xlink:href=\"/doi/suppl/10.1021%2Fja016384q\">Supporting Information Available</ext-link>\n</title><p>Crystal data, bond lengths and\nangles, SEM images, and EDS spectra of the CaNaPC crystals (PDF).\nThis material is available free of charge via the Internet at <uri xlink:href=\"http://pubs.acs.org\">http://pubs.acs.org</uri>.</p><title>References</title>", "clean_text": " Supporting Information Available \n\nCrystal data, bond lengths and angles, SEM images, and EDS spectra of the CaNaPC crystals (PDF). This material is available free of charge via the Internet at http://pubs.acs.org.\n\nReferences", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}], "cln_elements": [{"idx": 9, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"ja016384qt00001\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Inhibitory Action of NaPC and CaNaPC on Plaque Formation<italic toggle=\"yes\">\n<sup>a</sup>\n</italic>\n<sup></sup>\n</p>\n</caption>\n<oasis:table colsep=\"2\" rowsep=\"2\">\n<oasis:tgroup cols=\"4\">\n<oasis:colspec colname=\"1\" colnum=\"1\"></oasis:colspec>\n<oasis:colspec colname=\"2\" colnum=\"2\"></oasis:colspec>\n<oasis:colspec colname=\"3\" colnum=\"3\"></oasis:colspec>\n<oasis:colspec colname=\"4\" colnum=\"4\"></oasis:colspec>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry nameend=\"1\" namest=\"1\">treatment\ngroups</oasis:entry>\n<oasis:entry nameend=\"2\" namest=\"2\">treatment\u2009dosage\n(as\u2009mg\u2009H<sub>5</sub>PC)</oasis:entry>\n<oasis:entry nameend=\"3\" namest=\"3\">plaque\u2009weight\n(mg)<italic toggle=\"yes\">\n<sup>b</sup>\n</italic>\n<sup></sup>\n</oasis:entry>\n<oasis:entry nameend=\"4\" namest=\"4\">plaque\u2009weight\nreduction\u2009(%)\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry colname=\"1\">Group\u2009A\n</oasis:entry>\n<oasis:entry colname=\"2\">0\n</oasis:entry>\n<oasis:entry colname=\"3\">211\u2009\u00b1\u20099.244\n</oasis:entry>\n<oasis:entry colname=\"4\">0\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry colname=\"1\">Group\u2009B\n</oasis:entry>\n<oasis:entry colname=\"2\">9.7\n</oasis:entry>\n<oasis:entry colname=\"3\">147\u2009\u00b1\u20098.825\n</oasis:entry>\n<oasis:entry colname=\"4\">30\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry colname=\"1\">Group\u2009C\n</oasis:entry>\n<oasis:entry colname=\"2\">9.6\n</oasis:entry>\n<oasis:entry colname=\"3\">11\u2009\u00b1\u20094.444\n</oasis:entry>\n<oasis:entry colname=\"4\">95</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<p>\n<italic toggle=\"yes\">\n<sup>a</sup>\n</italic>\n<sup></sup>\u2009Data were processed to establish one way analysis of variance with\nsignificance determined as a pairwise comparison (Student\u2212Newman\u2212Keuls method).<italic toggle=\"yes\">\n<sup>b</sup>\n</italic>\n<sup></sup>\u2009Results are expressed as mean \u00b1 SEM for 10 plaques.\nStatistical significance was determined at the level of <italic toggle=\"yes\">P</italic> &lt; 0.001 for\nsingle groups and pairwise group comparisons.</p>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "Table 1. Inhibitory Action of NaPC and CaNaPC on Plaque Formation[^a]\n\n| treatment groups | treatment\u2009dosage (as\u2009mg\u2009H<sub>5</sub>PC) | plaque\u2009weight (mg)[^b] | plaque\u2009weight reduction\u2009(%) |\n|-------------------|---------------------------------------|-----------------------|----------------------------|\n| Group\u2009A           | 0                                     | 211\u2009\u00b1\u20099.244           | 0                          |\n| Group\u2009B           | 9.7                                   | 147\u2009\u00b1\u20098.825           | 30                         |\n| Group\u2009C           | 9.6                                   | 11\u2009\u00b1\u20094.444            | 95                         |\n\n[^a] Data were processed to establish one way analysis of variance with significance determined as a pairwise comparison (Student\u2212Newman\u2212Keuls method).\n[^b] Results are expressed as mean \u00b1 SEM for 10 plaques. Statistical significance was determined at the level of *P* < 0.001 for single groups and pairwise group comparisons.", "data": [[{"meta": {"name": "Group\u2009A", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "treatment\u2009dosage (as\u2009mg\u2009H5PC)", "value": "0", "unit": "mg", "condition": ""}, {"property name": "plaque\u2009weight (mg)", "value": "211\u2009\u00b1\u20099.244", "unit": "mg", "condition": ""}, {"property name": "plaque\u2009weight reduction\u2009(%)", "value": "0", "unit": "%", "condition": ""}]}, {"meta": {"name": "Group\u2009B", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "treatment\u2009dosage (as\u2009mg\u2009H5PC)", "value": "9.7", "unit": "mg", "condition": ""}, {"property name": "plaque\u2009weight (mg)", "value": "147\u2009\u00b1\u20098.825", "unit": "mg", "condition": ""}, {"property name": "plaque\u2009weight reduction\u2009(%)", "value": "30", "unit": "%", "condition": ""}]}, {"meta": {"name": "Group\u2009C", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "treatment\u2009dosage (as\u2009mg\u2009H5PC)", "value": "9.6", "unit": "mg", "condition": ""}, {"property name": "plaque\u2009weight (mg)", "value": "11\u2009\u00b1\u20094.444", "unit": "mg", "condition": ""}, {"property name": "plaque\u2009weight reduction\u2009(%)", "value": "95", "unit": "%", "condition": ""}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 1. Inhibitory Action of NaPC and CaNaPC on Plaque Formation[^a]\n\n| treatment groups | treatment\u2009dosage (as\u2009mg\u2009H<sub>5</sub>PC) | plaque\u2009weight (mg)[^b] | plaque\u2009weight reduction\u2009(%) |\n|-------------------|---------------------------------------|-----------------------|----------------------------|\n| Group\u2009A           | 0                                     | 211\u2009\u00b1\u20099.244           | 0                          |\n| Group\u2009B           | 9.7                                   | 147\u2009\u00b1\u20098.825           | 30                         |\n| Group\u2009C           | 9.6                                   | 11\u2009\u00b1\u20094.444            | 95                         |\n\n[^a] Data were processed to establish one way analysis of variance with significance determined as a pairwise comparison (Student\u2212Newman\u2212Keuls method).\n[^b] Results are expressed as mean \u00b1 SEM for 10 plaques. Statistical significance was determined at the level of *P* < 0.001 for single groups and pairwise group comparisons.\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"Group\u2009A\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"treatment\u2009dosage (as\u2009mg\u2009H5PC)\",\n                \"value\": \"0\",\n                \"unit\": \"mg\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"plaque\u2009weight (mg)\",\n                \"value\": \"211\u2009\u00b1\u20099.244\",\n                \"unit\": \"mg\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"plaque\u2009weight reduction\u2009(%)\",\n                \"value\": \"0\",\n                \"unit\": \"%\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"Group\u2009B\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"treatment\u2009dosage (as\u2009mg\u2009H5PC)\",\n                \"value\": \"9.7\",\n                \"unit\": \"mg\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"plaque\u2009weight (mg)\",\n                \"value\": \"147\u2009\u00b1\u20098.825\",\n                \"unit\": \"mg\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"plaque\u2009weight reduction\u2009(%)\",\n                \"value\": \"30\",\n                \"unit\": \"%\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n    {\n        \"meta\": {\n            \"name\": \"Group\u2009C\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"treatment\u2009dosage (as\u2009mg\u2009H5PC)\",\n                \"value\": \"9.6\",\n                \"unit\": \"mg\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"plaque\u2009weight (mg)\",\n                \"value\": \"11\u2009\u00b1\u20094.444\",\n                \"unit\": \"mg\",\n                \"condition\": \"\",\n            },\n            {\n                \"property name\": \"plaque\u2009weight reduction\u2009(%)\",\n                \"value\": \"95\",\n                \"unit\": \"%\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n]\n```"}}, {"idx": 2, "type": "figure", "classification": null, "content": "<fig fig-type=\"chart\" id=\"ja016384qc00001\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Schematic Structure of Phosphocitric Acid (H<sub>5</sub>PC)\n</p>\n</caption>\n<graphic orientation=\"portrait\" position=\"float\" xlink:href=\"ja016384qc00001.tif\"></graphic>\n</fig>", "clean_text": " 1  Schematic Structure of Phosphocitric Acid (H5PC)    ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 5, "type": "figure", "classification": null, "content": "<fig id=\"ja016384qf00001\" orientation=\"portrait\" position=\"float\">\n<label>1</label>\n<caption>\n<p>ORTEP diagram (50% probability ellipsoids) of CaNaPC. Important bond lengths and distances (\u00c5):\u2009 Ca\u00b7\u00b7\u00b7Ca 8.794(1), Ca\u00b7\u00b7\u00b7Na 4.3972(5), Ca(1)\u2212O(11) 2.388(2), Ca(1)\u2212O(3) 2.446(2), Ca(1)\u2212O(7) 2.477(1), Ca(1)\u2212O(8) 2.527(2), Ca(1)\u2212O(5) 2.586(2). O-attached protons and two hydrogen bonds (dashed lines) are shown. See Supporting Information for further structural details.</p>\n</caption>\n<graphic orientation=\"portrait\" position=\"float\" xlink:href=\"ja016384qf00001.tif\"></graphic>\n</fig>", "clean_text": " 1  ORTEP diagram (50% probability ellipsoids) of CaNaPC. Important bond lengths and distances (\u00c5): Ca\u22c5\u22c5\u22c5Ca 8.794(1), Ca\u22c5\u22c5\u22c5Na 4.3972(5), Ca(1)-O(11) 2.388(2), Ca(1)-O(3) 2.446(2), Ca(1)-O(7) 2.477(1), Ca(1)-O(8) 2.527(2), Ca(1)-O(5) 2.586(2). O-attached protons and two hydrogen bonds (dashed lines) are shown. See Supporting Information for further structural details.   ", "data": null, "include_properties": null, "intermediate_step": {}}], "metadata": {"doi": "10.1021/ja016384q", "title": "\nA Crystallographically Characterized\nNine-Coordinate Calcium\u2212Phosphocitrate Complex\nas Calcification Inhibitor in Vivo\n", "journal": "American Chemical Society", "date": "2001.09", "author_list": ["Demadis\nKonstantinos D.", "Sallis\nJohn D.", "Raptis\nRaphael G.", "Baran\nPeter"]}}